Medical Condition News

RSS

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials.

21 Sep 2010

Celera receives patent on KIF6 gene variant

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.

21 Sep 2010

National survey highlights need for greater awareness on lymphoma

While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States. Survey results showed a high number of adults (86 percent) remain unaware that there are 67 different types of lymphoma - 61 types of non-Hodgkin lymphoma and six types of Hodgkin lymphoma.

21 Sep 2010

FDA approves Mylan's generic Prograf Capsules ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tacrolimus Capsules, 0.5 mg, 1 mg and 5 mg, the generic version of Astellas' Prograf® Capsules, a treatment to prevent rejection in people who have received certain organ transplants.

21 Sep 2010

Project Blue Sky helps cancer patients to feel good

blue sky scrubs are making cancer patients feel good about themselves. Through Project Blue Sky, blue sky scrubs is able to provide patients with a fashion forward way to cover the most outward sign of sickness, hair loss.

21 Sep 2010

ADI releases World Alzheimer Report 2010

The World Alzheimer Report 2010 was released today to mark World Alzheimer's Day and heighten awareness of the global economic impact of Alzheimer's disease and related dementias.

21 Sep 2010

immatics raises EUR53.8million in Series C financing round

immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics' existing pipeline of advanced therapeutic cancer vaccine candidates.

21 Sep 2010

New MTWA technology is integrated in Quinton Q-Stress cardiac stress systems

Cambridge Heart, Inc., a developer of noninvasive diagnostic tests for cardiac disease, today announced the launch of its Microvolt T-Wave Alternans (MTWA) technology as an integrated part of industry-leading cardiac stress test systems manufactured and distributed by Cardiac Science Corporation. The MTWA technology, which can predict a patient's risk of sudden cardiac arrest (SCA), is now being offered to new and existing users of Cardiac Science's Quinton Q-Stress cardiac stress systems.

21 Sep 2010

NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction

The University of Maryland School of Pharmacy has received a prestigious $3.7 million grant to develop a drug to treat cocaine addiction based on an active ingredient found in some Chinese prescription medicines.

21 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Oxy-Powder supplement clears clinical trials for Irritable Bowel Syndrome

The popular nutraceutical health supplement, Oxy-Powder has passed clinical trials for Irritable Bowel Syndrome (IBS) with a 99.9 percent success rate.According to the NIH, approximately 20% of Americans suffer from the symptoms of IBS, which qualifies it as one of the most common medical problems in the United States.

21 Sep 2010

ImmunoGen commences clinical testing with SAR566658 anticancer compound

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen's product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 and marked, sustained pipeline growth thereafter.

21 Sep 2010

ASM awards UTHealth student 3-year, $33,000 fellowship for study of molecular details of protein folding in cells

Jennifer Abrams, a graduate student at The University of Texas Health Science Center at Houston (UTHealth), has been awarded a three-year, $33,000 fellowship from the American Society for Microbiology (ASM) to support her innovative research into the molecular causes of protein misfolding diseases like Alzheimer's, Lou Gehrig's and Parkinson's.

21 Sep 2010

Over 80% of hospitalized patients suffer more severe pain than necessary

More than 80% of hospitalized patients suffer more severe pain than necessary. This is the conclusion of Christoph Maier (Bochum University Hospital, Bochum, Germany) and his coauthors in their interim report of the Pain-Free Hospital Project ("Schmerzfreies Krankenhaus"), which appears in the current issue of Deutsches -rzteblatt International. The project, which was initiated in 2003, has the goal of improving pain management in hospitals across Germany.

21 Sep 2010

Study says PTSD veterans suffer from more medical conditions

Is the US health system comprehensively meeting the needs of returning veterans? With the recent attention to mental illness in returning soldiers, and post traumatic stress disorder (PTSD) in particular, little research has focused on the medical care needs of those returning from Operation Enduring Freedom/Operation Iraqi Freedom, according to Dr. Susan Frayne, from the VA Palo Alto Health Care System and Stanford University, and colleagues.

21 Sep 2010

Young victims of cyber bullying more likely to suffer from depression

Young victims of electronic or cyber bullying — which occurs online or by cell phone — are more likely to suffer from depression than their tormentors are, a new study finds.

21 Sep 2010

Study reveals molecular steps for pneumonia therapy

A structural molecule and the cellular pump that regulates its levels influence the severity of pneumonia and could provide new ways of treating the lung infection, which is a leading cause of hospitalization and death, according to scientists at the University of Pittsburgh and the University of Iowa. Their findings are available online in Nature Medicine.

21 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010

Voice disorders are not benign nuisances that go away

Two-thirds of Americans with voice problems don't seek medical care either because they don't know treatment is available or because they think the problem will just go away, according to a new study conducted at the Duke Voice Care Center.

21 Sep 2010